期刊文献+

CRM1选择性抑制剂KPT-330对急性白血病细胞凋亡的诱导作用及分子机制

下载PDF
导出
摘要 目的:探讨CRM1选择性抑制剂KPT-330对急性白血病细胞凋亡的诱导作用及分子机制。方法:培养白血病K562细胞株,分为对照组(n=20)与KPT-330处理组(n=40)采用CCK-8实验检测KPT-330对K562细胞增殖的影响,流式细胞仪法测定K562细胞凋亡及细胞周期,Realtime PCR法检测CRM1与Caspase-3 mRNA表达量。结果:在K562细胞中CRM 1呈高表达,KPT-330可呈剂量依赖性地抑制K562细胞增殖且促进细胞凋亡,使G2期细胞减少,subG1期细胞增多,造成细胞周期紊乱。KPT-330可呈剂量依赖性下调CRM1表达,同时上调Caspase-3表达。结论:CRM 1选择性抑制剂KPT-330可以明显促进白血病细胞凋亡,同时抑制其增殖,可能与活化Caspase-3相关。
作者 韦岩
出处 《中外医学研究》 2019年第22期65-67,共3页 CHINESE AND FOREIGN MEDICAL RESEARCH
  • 相关文献

参考文献5

二级参考文献29

  • 1顾龙君.儿童急性髓细胞白血病诊疗建议[J].中华儿科杂志,2006,44(11):877-878. 被引量:159
  • 2Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratifica- tion, and therapy of pediatric acute leukemias: an update [J]. Clin Oneol, 2011, 29(5):551-565.
  • 3Filoni DN, Pesi R, Careddu MG, et al. Initial studies to define the physiologic role of oN-II [J]. Nucleosides Nucleotides Nucleic Acids, 2011, 30( 12):1155-1160.
  • 4Tozzi MG, Camici M, Pesi R, et al. Nucleoside phosphotransfer- ase activity of human colon carcinoma cytosolic 5'-nueleotidase [J]. Arch Biochem Biophys, 1991, 291 (2):212-217.
  • 5Pieters R, Huismans DR, Loonen AH, et al. Relation of 5'- nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia[ J]. Leuk Res, 1992, 16(9):873-880.
  • 6Hubeek I, Stain RW, Peters GJ, et al. The human equilibrativenucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia[J]. Br J Cancer, 2005, 93 (12):1388-1394.
  • 7Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to cytarabine in AML patients[J]. Leuk Res, 2002, 26(7): 621-629.
  • 8Galmarini CM, Thomas X, Graham K, et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine[J]. Br J Haematol, 2003, 122( 1 ):53-60.
  • 9Suzuki K, Sugawara T, Oyake T, et al. Clinical significance of high-Kin 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome [J]. Leuk Res, 2007, 31 (10):1343- 1349.
  • 10Galmarini CM, Thomas X, Calvo F. Mechanisms of resistance to cytarabine in relapsing acute myeloid leukemia (AML) patients [J].Blood (ASH Annual Meeting Abstracts), 1999, 94: Abstract1249.

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部